Asymptotic distribution of the mean survival time based on the Kaplan-Meier curve with an extrapolated 'tail' is derived. A closed formula of the variance estimate is provided. Asymptotic properties of the estimator were studied in a simulation study, which showed that this estimator was unbiased with proper coverage probability and followed a normal distribution. An example is used to demonstrate the application of this estimator.
INTRODUCTION
In many clinical trials, mean survival is difficult to estimate because of censoring or insufficient follow-up. As an alternative, Irwin [1] proposed restricted mean survival time to estimate expected lifetime restricted to a chosen time point T. Restricted mean survival time is defined as the integration of survival function from time 0 to a chosen time point T, which essentially is the area under the survival curve from time 0 to T. Test statistics based on the difference of two restricted mean survival times were derived to compare the distributions of survival time from two treatment groups as an alternative test under the situation of non-proportional hazard ratio [2] [3] [4] [5] [6] [7] . Restricted mean survival is also widely used to estimate quality-adjusted survival in patient outcome research [8, 9] .
The choice of restriction time T is often subjective and hard to justify. Karrison [2] discussed a method to choose T on the basis of the sample size. Literatures in quality-adjusted survival [8, 9] suggest choosing median follow-up time as T. However, in practice, the expected survival time (i.e., mean survival time) is much more meaningful for patients than the expected survival time up to a chosen time point T (i.e., restricted mean survival time). Estimating mean survival time is possible if the last observation on the study was an event and survival curve drops to 0 at the end, although the estimation could be unstable because of the small number of risk set at the tail of the survival curve. When the last observation on the survival curve is censored and the curve does not drop to 0 at the end, Efron [10] assumed 0 beyond the last observation. Moeschberger and Klein [11] and Klein et al. [12] investigated ways to extrapolate the Kaplan-Meier survival curve to 0. The extrapolation methods add a 'tail' to the Kaplan-Meier curve beyond the last observed time point. The 'tail' is estimated by a parametric function fit to the data. In other words, the tail is imputed on the basis of the parametric survival function estimated from the data. Gelber et al. [13] proposed estimating mean survival on the basis of the extrapolated Kaplan-Meier survival curve. Commercial software Stata (Stata Corp., College Station, TX, USA) provides an option to calculate the mean survival using this extrapolation method without providing the variance estimate (www.stata.com/help.cgi?stci). However, to our knowledge, the statistical inference of mean survival estimator based on the extrapolated Kaplan-Meier curve has not been derived. Especially, the variance estimate of such estimator was obtained using a bootstrap method because no closed formula was available. In this article, the estimator of the mean survival time based on extrapolated Kaplan-Meier survival curve is referred to as the hybrid estimator because it includes a nonparametric estimate of survival and a parametric extrapolation of the tail beyond the last observation of the survival curve. Statistical inferences of the hybrid estimator, including the closed form of the variance estimate, are derived, and asymptotic properties are evaluated.
The article is organized as follows. In Section 2, notations are defined, and the hybrid estimator and its statistical inferences are derived. A simulation study is reported in Section 3 to evaluate the asymptotic properties of the hybrid estimator. In Section 4, we apply our methods to estimate the mean survival time and treatment effects from an oncology clinical trial. A discussion and summary is presented in Section 5. 
NOTATIONS AND METHODS
In fact, one could choose the adjacent time point to be a time point (t 1 ) earlier than the last observed survival time ( , t 1 < ) and let the parametric extrapolation start at t 1 because the Kaplan-Meier tail estimate is unstable due to few available data. Nevertheless, the results in this section can be extended naturally to obtain the variance estimate. Let T i denote the survival time, and C i is the censoring time for the ith subject. Assume C i is independent of T i . The observed time is given by X i D min.T i , C i /, and the censoring indicator
To estimate KM , we use counting process notations. Let Y.t/ be the number of subjects at risk at time t and N i .t/ be the count of events at time t for the ith subject. .t/ denotes the accumulate baseline hazard function.
It can be shown that
where
Under some regular conditions [15] Because˜i(t), i , and i are all independent and identically distributed with zero expectation, the covariance coefficient for the Kaplan-Meier and parametric extrapolated tail can be derived as
We have O P ! P and can obtain O H N.0, H /, where
All the terms mentioned in the preceding text can be consistently estimated by their sample analogs. The hybrid mean survival hypothesis testing is based on Z-test. However, as discussed in many literatures [8, 17] , the parametric function estimated from the data usually has poor fitting at the tail of the survival curve. This is because the majority of the data occur at the early part of the curve and drive the overall fitting of the parametric function. For example, a Weibull distribution can fit the data well when judging the goodness-of-fit from the entire course of the survival curve. However, the local fitting at the tail may be poor.
In such cases, we define another hybrid estimator of mean survival
This estimator differs from (2.1) in such a way that the extrapolated tail is estimated via data beyond time point t 0 , conditional on t > t 0 . In other words, the parametric tail is estimated 'locally' and thus results in a better fit to the tail of the survival curve. This parametric tail is then attached to the Kaplan-Meier estimate O S KM .t 0 / at time t 0 to obtain the estimated survival function for the period of time t > t 0 :
We defineˇ as the parameter vector of the distribution fit to local data. To estimateˇ , we write the likelihood function as 
Similarly, all terms mentioned in the preceding text can be estimated consistently by their sample counterparts. Z-test could be used for the hypothesis testing.
SIMULATION STUDY
We conducted a simulation study to assess the asymptotic properties of the hybrid estimator in Section 2. Data were generated randomly from four scenarios. In the first scenario, the data were generated from a Weibull distribution S.t/ D expf .t=e / 1= g with parameters D 1.5 and D 1.2. In the second and fourth scenarios, the data were created from a piecewise Weibull distribution with parameters 1 D 2.2 and 1 D 2.0 when t < 5, and 2 D 2.5 and 2 D 0.4 when t 5. In scenario 3, data were from an exponential distribution S.t/ D expf tg with D 0.2. Event time T i (n D 100, 200, 300) was generated from one of these distributions. Independent censoring C i was generated from uniform distribution between (a, b), where a and b values vary (Table I) As a result, the adjacent time may vary among replications but would always be less than or equal to b. t 0 and are different. Time t 0 is the cutoff beyond which a chosen parametric form is fit in (2.3) . Time is the maximum observation time, from which the extrapolated tail starts and goes to infinity. One thousand replications were generated for each scenario.
For all four scenarios, the true distribution forms were used as S P .t/ to fit the curve. For scenarios 1 and 2, S P .t/ were estimated on the basis of all data. In other words, hybrid estimator (2.1) was used to estimate mean survival time. Note that, for scenario 2, we fit a piecewise Weibull distribution to all data to obtain S P .t/, and we did not force the tail to be adjacent to the Kaplan-Meier curve. Therefore, the mean survival was still estimated using estimator (2.1). For scenarios 3 and 4, only the data beyond time t 0 D 5 were used to fit S P .t;ˇ jt > t 0 /, and then the parametric form was attached to the Kaplan-Meier estimate at time t 0 , S KM .t 0 /, to form the final function S P .t; t 0 ,ˇ / D S KM .t 0 /S P .t;ˇ jt > t 0 /. In other words, hybrid estimator (2.3) was used to estimate mean survival time. For all four scenarios, the adjacent time point is chosen to be the maximum survival time observed. The percent bias, coverage probability, empirical standard error (ESE), and asymptotic standard error (ASE) of the mean survival estimate were calculated (Table I) . ESE is the sample standard error of mean lifetime estimate across all replications. ASE is the average of the derived asymptotic standard error based on our method from each of the replications.
In all four scenarios, the biases of the hybrid estimator were close to 0 (<˙3%). The ESE were closed to the ASE. The coverage probabilities were close to the desired level of 95%. As the sample size went up or the censoring rate went down, the bias and the standard error became smaller and smaller. The choices of 75 percentile and 95 percentile time as the adjacent time point resulted in similar findings (data not shown). Therefore, the asymptotic properties derived in Section 2 were verified.
To study the robustness of the hybrid estimator to misspecification of the underlying data distribution, we generated data from Weibull (scenarios 5 and 6, Table II), log-logistic (scenario 7), and log-normal (scenario 8) distributions and estimated mean survival time by using the hybrid estimator (2.3) with exponential distribution fit to the local data at the tail. Log-logistic survival function was expressed as S.t/ D 1=f1Cexp. = /t 1= g. Log-normal density function was shown as f .t/ D expf OElog.t/ 2 =2 g= p 2 . It was already shown in Su and Fang [17] that the hybrid estimator (2.1) was not robust to mis-specification of the underlying data distribution and therefore not investigated here.
For all four scenarios, the percent biases of the mean survival were small (<5.6%). The ESE was close to ASE, which indicated that the derived formulas of the asymptotic of the hybrid estimator were valid. However, the coverage probabilities were less than 95% for log-logistic and log-normal distributions and associated with larger biases ( 3.21% and 5.56%, respectively). These results suggest that the hybrid estimator (2.3) is fairly robust to mis-specification of the underlying data distribution, although the biases in parameter estimates are inevitable.
EXAMPLE
As an illustration, we estimated the mean survival time with the hybrid estimator for data generated from a randomized, placebo- Hybrid estimator (2.3) with exponential distribution fit to the tail was used in this table. ESE, empirical standard error; ASE, asymptotic standard error.
variable, progression-free survival (PFS), defined as the duration from randomization to disease progression or death, whichever occurred first. The primary objective was to compare the PFS time between the two arms.
The difference in median PFS time was 1.1 months with a confidence interval of (0.4, 2.6) from Kaplan-Meier estimate, which indicates a small benefit of adding B to A. However, the hazard ratio estimated from a Cox regression model was 0.68, and the p-value was 0.0002 from the log-rank test. The hazard ratio indicates a reasonably large magnitude of risk reduction (32%), and the p-value suggested that the survival functions were significantly different for the two groups, which were not reflected by the difference in median survival. Further evaluation of the Kaplan-Meier plot revealed that the curves came together at 50% of survival probability although separated elsewhere.
Above phenomenal was not uncommon in survival analysis. Another example can be found in the prescription information of Vectibix®, a drug for metastatic colorectal cancer [18] . The Kaplan-Meier curves for the primary end point (progression-free survival, PFS) in the registration trial of Vectibix® showed an interesting pattern where the survival curve for the treatment arm was well separated from the control arm, whereas two curves were very close at the median time. The log-rank test indicated a significant improvement in PFS (p < 0.0001), whereas the difference in medians was close to 0. In such case, researchers used mean survival time to measure the magnitude of treatment benefit. Calculating mean survival time was possible for that trial as the follow-up period was long enough for the survival curves in both arms to drop to 0 at the end.
For our example, the last observation of the control arm on the Kaplan-Meier curve was censored, and the curve did not drop to 0. Therefore, only restricted mean survival could be estimated. Instead, we estimated the mean survival with the hybrid estimator. A wide choice of distributions including Weibull, exponential, log-logistic, logistic, and log-normal were explored to fit the data overall or by method (2.1). We evaluated the model fitting through Cox-Snell residual plots [16] . However, none of them gave satisfying fitting, which meant that the hybrid mean survival estimator (2.1) cannot be applied, and we had to try the estimator (2.3). It was observed that the hazard rate seems to change after month 6. Thus, an exponential distribution was fit to the curve beyond t 0 D 6 months. The adjacent time point was chosen to be 15 months because sample survival was only 5% beyond that time point. In other words, the extrapolated tail was used to estimate the survival curve beyond to obtain a hybrid survival curve for mean survival calculation. Figure 1 (I) presents the Kaplan-Meier estimate and the fitted distribution function that was used to extrapolate the survival curve beyond
. Figure 1 (II) shows the whole hybrid curve used to estimate mean lifetime. Fitted distributions and parameters were listed in Table III along with the hybrid mean survival estimated for each arm and difference between the two arms. The estimated difference in hybrid mean survival is 2.2 months. This magnitude better reflects the observed benefit from the estimated hazard ratio and the log-rank test.
DISCUSSION
In this article, we estimated mean survival time with a hybrid estimator in two forms of (2.1) and (2.3) on the basis of an extrapolated Kaplan-Meier survival curve beyond the last observation. This hybrid estimator of mean survival was shown to be unbiased and followed a normal distribution. A closed formula of the variance estimate for the hybrid estimator was derived and shown to provide the right coverage probability in the simulation study.
Estimating the variance of a hybrid estimator such as ours has always been a challenge in the literatures and is usually obtained using re-sampling method [13] . The closed formula derived here will benefit researchers and software developers. Traditionally, median survival is used as the standard measure of the center of data distribution, whereas mean survival is rarely acceptable because of censoring and skewed distribution of survival data. In some situations, such as adjuvant oncology trials, the event rate is so low that the median survival time cannot be Table III for distribution and parameter values).
estimated. Mean survival is used instead, for example, calculating quality-adjusted lifetime and assessing relative cost-effectiveness in health economics [19] . One of the reasons that mean survival has not been widely used in the medical community is that it is difficult to estimate because of censoring and insufficient followup. Restricted mean survival was an alternative. However, choosing the restriction time is hard to justify and explain. The hybrid estimator provides an option to estimate mean survival without having to choose a restricted time, which will make the concept of mean survival easier to understand for patients. Using difference in mean survival to quantify the treatment benefit presents certain advantages in some situations as shown in the example.
The statistical inferences derived in the article can be easily extended to the calculation of quality-adjusted survival, which is essentially a weighted mean survival time. It is a major challenge in patient-reported outcome research that the quality-adjusted survival calculated on the basis of restricted mean survival cannot be extended to the point beyond restriction time T. Gelber et al. [13] investigated the quality-adjusted survival based on the extrapolated survival curves and obtained the confidence interval from bootstrap. Their estimator is essentially the same as our estimator (2.3).
The main limitation of the hybrid estimator is that the performance of the hybrid estimator depends on the goodness of fit of the parametric model. Certain model diagnosis has to be done [16] . The hybrid estimator (2.3) has certain advantages and flexibility that could achieve better model fitting. It is more important to obtain a good fitting at the tail part of the survival curve. If there is no appropriate parametric model that provides good fitting of the survival curve, especially at the tail part, one should avoid using the hybrid estimator and pursue restricted mean survival or median survival time instead. It is important to point out that all extrapolations beyond observed range of data are associated with untestable assumptions. Should the true distribution beyond last observed time change significantly, the hybrid mean survival estimator would provide biased estimate. In addition, the formulas in this article cannot be used without individual patient-level data. In the absence of individual patient-level data, one must turn to other methods, such as method of moments or regression analysis.
It is important to point out that it is not acceptable to use a hybrid estimator as an alternative to designing for sufficient follow-up period. In situations where it is difficult to have a sufficient follow-up period, such as adjuvant oncology trials, the hybrid estimator of mean survival could be considered as an alternative. Future research in this area includes exploring the possibility of deriving a robust variance estimator of the hybrid mean survival.
